the product in the database has an inactive status
indications:
Peptic ulcer of the stomach and duodenum. Reflux oesophagitis. Zollinger-Ellison syndrome.
Composition:
1 vial contains 40 mg omeprazole.
Action:
Proton pump inhibitor (H+/ K+-ATP-azy) in the parietal cells of the stomach. The effect of the drug depends on the dose and leads to a reduction in the secretion of hydrochloric acid in the stomach, both basal and stimulated, regardless of the type of stimulus. It reduces the acidity of gastric juice and increases the gastrin concentration proportionally to reduce acidity. It is 95% bound to plasma proteins. Metabolism occurs in the liver and renal excretion (80%) and faecal excretion (20%). T0,5 is 30-90 min. It penetrates into breast milk.
Contraindications:
Hypersensitivity to the components of the preparation. Simultaneous treatment with atazanavir.
Precautions:
The safety of use in children has not been established.
Pregnancy and lactation:
It may be used during pregnancy and breast-feeding only if the expected benefit to the mother outweighs the potential risk to the fetus or the fed baby.
Side effects:
Common: headache, diarrhea, constipation, abdominal pain, nausea, vomiting, bloating. Uncommon: fatigue, rash, pruritus, urticaria, change in liver enzymes, paresthesia, dizziness, drowsiness, sleep disorders. Rare: increased sweating, peripheral edema, hyponatremia, hypersensitivity reactions (angioneurotic edema, fever, anaphylactic shock), leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, gynaecomastia, dry mouth, taste disorders, stomatitis, gastrointestinal candidiasis, loss of hair, photosensitivity, erythema multiforme, encephalopathy in patients with pre-existing severe liver disease, hepatitis with jaundice or without jaundice, hepatic failure, bronchospasm, joint pain, muscle weakness, muscle pain, transient confusion, agitation, aggression, depression and hallucinations (especially in severely ill patients), blurred vision, interstitial nephritis. In individual cases: Stevens-Johnson syndrome, toxic epidermal necrolysis. Treatment with Omeprazole may lead to a slight increase in the risk of gastrointestinal infections caused by microorganisms such as:Salmonella andCampylobacter.
Dosage:
Intravenously.Peptic ulcer of the stomach or duodenum, reflux oesophagitis: 40 mg once a day; usually the treatment is carried out for 2-3 days and continues with the oral preparation.Zollinger-Ellison syndrome: dosage is determined individually. The infusion should last 20-30 minutes. In patients with liver failure, clearance of omeprazole is significantly reduced.
(C)
